Journal
CLINICAL NUCLEAR MEDICINE
Volume 46, Issue 11, Pages 940-942Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000003730
Keywords
F-18-FDG; Ga-68-FAPI; PET/CT; radioiodine-refractory; differentiated thyroid cancer
Funding
- medical and health guidance projects of Xiamen [3502Z20209269, 3502Z20189010]
Ask authors/readers for more resources
Ga-68-FAPI is a promising alternative to F-18-FDG for detecting tumor recurrence and metastases in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), showing a better signal-to-background ratio, especially for detecting small pulmonary metastases. It can also be used for guiding FAP-targeted radionuclide therapy.
F-18-FDG PET/CT is a useful imaging modality for detecting disease recurrence and metastases in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). However, the sensitivity of F-18-FDG PET/CT in RAIR-DTC is not very satisfactory. Ga-68-FAPI is a promising PET tracer that allowed imaging of various types of cancer. In this case, Ga-68-FAPI showed a far better signal-to-background ratio than F-18-FDG for detecting the RAIR-DTC metastatic lesions, especially for detecting the small pulmonary metastases. Therefore, Ga-68-FAPI may be a promising alternative to F-18-FDG for detecting tumor recurrence and metastases in RAIR-DTC. It could also be used for guiding FAP-targeted radionuclide therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available